期刊文献+

P-gp和GST-π在胆囊癌中的表达与化疗耐药的研究 被引量:3

Expression and chemotherapeutical resistance of P-glycoprotein and glutathione S-transferase in gallbladder carcinoma
下载PDF
导出
摘要 目的 通过检测胆囊癌组织中P -糖蛋白 (P - gp)和胎盘型谷胱苷肽S转移酶(GST -π)的表达状况 ,揭示胆囊癌对化疗不敏感的内在机制。方法  38例胆囊癌组织石蜡标本 ,12例结石性胆囊炎组织石蜡标本分别进行生物素蛋白链菌素 -生物素 -过氧化物酶免疫组织化学染色 ,按照既定的阳性标准判定染色结果。结果 P - gp和GST -π在胆囊癌的表达阳性率分别为 78.9%和 6 5 .7% ,而在胆囊良性疾病中两者阳性率分别为 2 5 %和 16 .6 % ,两者比较均具有显著性差异 (P <0 .0 5 )。结论 P - gp、GST Objective By approach the situations of expression of P-glucoprotein(P-gp) and placental glutathione S-transferase(GST- π) as a biomarker in gallbladder carcinoma(GC) to reveal the intrinsic mechanism of poor response of GC to chemotherapy. Method By means of the streptavidin-biotin-peroxidase complex staining method and according to the stand of positive-stainning,the expression of the P-gp and GST-π in tissues of GC and chronic calulous cholecystitis(CCC) were determined in 38 cases of GC and 10 cases of CCC. Result The positive rate of P-gp and GST-π were 78.9% and 65.7% respectively in GC and were higher that in benign(25% and 16.6%), the difference were significantly(P<0.05). Conclusions The higher expression of P-gp and GST- π may be the main reason of resistance of GC patients to chemotherapeutical agents.
作者 穆永臣
机构地区 中原油田总医院
出处 《新乡医学院学报》 CAS 2001年第3期162-164,共3页 Journal of Xinxiang Medical University
关键词 胆囊癌 化疗耐药 P-糖蛋白 胎盘型谷胱苷肽S转移酶 治疗 gallbladder carcinoma chemoteraputical resistance P-glycoprotein placnetal glutathione S-tansferase
  • 相关文献

参考文献1

共引文献12

同被引文献43

  • 1苏剑东,吴灵飞.NF-kB与细胞凋亡[J].世界华人消化杂志,2007,15(12):1411-1416. 被引量:51
  • 2Willman CL. Immunophenolyping and cytogenetics in older adults with acute myeloid leukemia : significance of expression of the multidrug resistance gene- 1 (MDR1) [ J]. Luekemia,1996,10(suppl 1 ) :s33 -35.
  • 3Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrugresistance gene in human tumors and tissues[ J ]. Pro Natl Acad Sci USA,1987,84(3) :256 -269.
  • 4Cullinan S, Moertel CG, Wieand HS,et al. A phase Ⅲ trial on the therapy of advanced pancreatic carcinoma[ J ]. Cancer, 1990, 65 ( 1 ):2207 -2212.
  • 5Kelsen D. The use of chemotherapy in the treatment of advanced gastric and pancreas cancer [ J ] . Semin Oncol,1994, 21(suppl 7) :58 -66.
  • 6Takada T, Kato H, Matsushiro T, et al. Comparison of 5 - fluorouracil,doxorubicin and mitomycin - C with 5 - fluorouracil alone in the treatment of pancreatic - biliary carcinomas [ J ].Oncol,1994, 51(3) :396 -400.
  • 7Arbuck SG. Overview of chemotherapy for pancreatic cancer [ J ]. Int J Pancreatol,1990,12(3) :209 -222.
  • 8Carter SK. The integration of chemotherapy into a combined modality approach for cancer treatment V1. Pancreatic adenocarcinoma [ J ]. Cancer Treat Rev, 1975, 3 ( 3 ) : 193 -214.
  • 9Takada T, Nimura Y. Prospective randomized trial of 5 - fluorouracil, doxorubicin and mitomycin C for non - resectable pancreatic and biliary carcinoma : multicenter randomized trial [ J ] . Hepatogastroenterology, 1998, 45 (24) :2020 -2026.
  • 10Choi CW, Choi Kl,Seo JH, e t a l.Effects of 5 - Fluorouracil and Leucovorin in the Treatment of Pancreatic -Biliary Tract Adenocarcinomas [ J ].Am J Clin Oncol, 2000, 23 (4) :425 - 428.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部